

AMENDMENTS

In the specification:

Please insert the attached "Sequence Listing" comprising SEQ ID NOs: 1-50 into the above-referenced application.

Please replace the paragraph at page 79, lines 4 through 13, with the following paragraph:

"Example 3. Functional assay for GPCR α 11

GPCR α 11 expressing clones have been obtained by transfection of CHO-K1 cells coexpressing mitochondrial apoaeguorin and Galpha16, limit dilution and selection by northern blotting. Positive clones were used for screening with a reference peptidic library containing 250 peptides and neuropeptides at a concentration of 100 nM. A specific activity was obtained with angiopeptin (D-Nal-Cys-Tyr-D-trp-Lys-Val-Cys-Thr-NH₂ (SEQ ID NO : 35) with a disulfide bridge between the two cysteines) and confirmed by a dose response curve (see Figure 15). Additional related peptides were tested using the same cells. Amongst the different peptides tested, somatostatin analog (D2-Nal-Cys-Tyr-D-trp-Lys-Val-Cys-D2-Nal-NH₂; SEQ ID NO : 36) exhibited similar affinity. Somatostatin 14 has no activity on GPCR α 11."

REMARKS

In the paragraph at page 79, lines 4 through 13, the typographical error in NaI is amended to Nal. D-Nal and D2-Nal are defined in the sequence listing as meaning beta-(1-Naphthyl)-D-alanyl and beta-(2-Naphthyl)-D-alanyl respectively.


This amendment adds no new matter.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments".

Respectfully submitted,

Mark J. Fitzgerald
Reg. No. 45,928 A
Kathleen M. Williams

Date: July 10, 2002


Kathleen M. Williams, Ph.D.
Registration No.: 34,380
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Telephone: (617) 239-0100 Fax: (617) 227-4420